within Pharmacolibrary.Drugs.ATC.J;

model J05AR21
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.64,
    Cl             = 1.6666666666666667e-05,
    adminDuration  = 600,
    adminMass      = 50 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0174,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.01933333333333333,
    Tlag           = 30.0
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>J05AR21</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Dolutegravir and rilpivirine is a fixed-dose combination antiretroviral medication used for the treatment of HIV-1 infection in adults who are virologically suppressed. Dolutegravir is an integrase strand transfer inhibitor (INSTI) and rilpivirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI). This combination is currently approved and marketed.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy adult HIV-negative volunteers after single oral administration of fixed-dose combination tablet of dolutegravir and rilpivirine.</p><h4>References</h4><ol><li><p>Turley, SL, &amp; Fulco, PP (2017). Enteral Administration of Twice-Daily Dolutegravir and Rilpivirine as a Part of a Triple-Therapy Regimen in a Critically Ill Patient with HIV. <i>Journal of the International Association of Providers of AIDS Care</i> 16(2) 117–119. DOI:<a href=&quot;https://doi.org/10.1177/2325957417692678&quot;>10.1177/2325957417692678</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/28198203/&quot;>https://pubmed.ncbi.nlm.nih.gov/28198203</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end J05AR21;
